Abnormal proliferation and motility of
retinal pigment epithelial cells leads to
proliferative vitreoretinopathy (PVR).
Melatonin is a known effective antitumour and anti-invasive agent, but whether it affects the formation and underlying mechanisms of PVR remains unclear. In this study, the results of the MTT assay, colony formation and
propidium iodide (PI) staining with flow cytometry revealed that
melatonin dose dependently inhibited
epidermal growth factor (
EGF)-induced proliferation of human ARPE-19 cells. Furthermore,
melatonin reduced
EGF-induced motility by suppressing
cathepsin S (CTSS) expression. Pretreatment with ZFL (a CTSS inhibitor) or overexpression of CTSS (pCMV-CTSS) significantly inhibited
EGF-induced cell motility when combined with
melatonin.
Epidermal growth factor induced the phosphorylation of AKT(S473)/mTOR (S2448) and
transcription factor (c-Jun/Sp1) signaling pathways. Pretreatment of
LY294002 (a PI3K inhibitor) or
rapamycin (an mTOR inhibitor) markedly reduced
EGF-induced motility and p-AKT/p-mTOR/c-Jun/Sp1 expression when combined with
melatonin. Taken together, these data indicate that
melatonin inhibited
EGF-induced proliferation and motility of human ARPE-19 cells by activating the AKT/mTOR pathway, which is dependent on CTSS modulation of c-Jun/Sp1 signalling.
Melatonin may be a promising therapeutic
drug against PVR.